Skip to main content
SpringerLink
Log in

Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy

  • Current Opinion
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

This article lays the background for, and discusses the practical issues surrounding, the adjunctive use of the last four antiepileptic drugs (AEDs) to be licensed for the treatment of pharmacoresistant focal seizures in the UK and elsewhere. More than 30 % of adolescent and adult patients will not be fully controlled on the currently available therapeutic armamentarium. After not responding to their first three AED schedules, only a handful of patients attained seizure freedom on subsequent regimens. To optimise the response to any new AED in this setting, it is often necessary to reduce the existing drug burden. The pharmacology, tolerability and safety, and everyday use of lacosamide, eslicarbazepine acetate, retigabine (ezogabine) and perampanel will be reviewed and discussed. This will be accompanied by data from prospective audits with each drug undertaken at the Western Infirmary in Glasgow, Scotland, and a report of their successful introduction in an illustrative case. Overall, there is a large variation in the course of refractory epilepsy and the effect of AED therapy on this process seems minimal. Nevertheless, a number of patients will benefit from the introduction of each new AED, with some becoming seizure-free.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lőscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.

    Article  PubMed  Google Scholar 

  2. Brodie MJ, Covanis A, Lerche H, Perucca E, Sills GJ, White S. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 2011;21:331–41.

    Article  PubMed  Google Scholar 

  3. Brodie MJ. Road to refractory epilepsy: the Glasgow story. Epilepsia. 2013;54(Suppl 2):5–8.

    Article  CAS  PubMed  Google Scholar 

  4. Chen Z, Brodie MJ, Liew D, Kwan P. Long-term outcome of 1805 people with newly diagnosed epilepsy. In: Presented at the 31st international epilepsy congress, 5–9 Sep 2015; Istanbul.

  5. Lőscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia. 2011;52:657–78.

    Article  PubMed  Google Scholar 

  6. Brodie MJ, Barry SJE, Bamagous GA, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Brodie MJ, Kelly K, Stephen LJ. Prospective audits with new antiepileptic drugs: insights into response. Epilepsy Behav. 2014;31:73–6.

    Article  PubMed  Google Scholar 

  8. Brodie MJ, Sills GJ. Combining antiepileptic drugs: rational polytherapy. Seizure. 2011;20:369–75.

    Article  PubMed  Google Scholar 

  9. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77.

  10. Hao X, Goldberg D, Kelly K, Stephen L, Kwan P, Brodie MJ. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy. Differences between populations with newly diagnosed and chronic epilepsy. Epilepsy Behav. 2013;29:4–6.

    Article  PubMed  Google Scholar 

  11. Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, On behalf of the SOPHIE Study Group, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52:2181–91.

  12. Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res. 2012;98:194–8.

    Article  CAS  PubMed  Google Scholar 

  13. Weschler RT, Li G, French J, O’Brien TJ, D’Cruz O, Williams P, On behalf of the ALEX-MT Study Group, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historically-controlled, multicentre double blind study. Epilepsia. 2014;55:1088–98.

  14. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308–17.

  15. Halasz P, Kalvianen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Herbert D, Sullivan T, On behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–53.

  16. Chung S, Sperling MR, Biton V, Krauss G, Herbert D, Rudd GB, On behalf of the SP754 Study Group, et al. Lacosamide as adjunctive therapy for partial-onset seizures? A randomized controlled trial. Epilepsia. 2010;51:958–67.

  17. Stephen J, Brodie MJ. Pharmacotherapy of epilepsy. Newly approved and developmental agents. CNS Drugs. 2011;25:89–107.

    Article  CAS  PubMed  Google Scholar 

  18. Errington AC, Stőhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157–69.

  19. Saké J-K, Hebert D, Isojarvi J, Doty P, De Backer M, Davies SK, et al. A pooled analysis of lacosamide clinical trial grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24:1055–8.

    Article  PubMed  Google Scholar 

  20. Cross SA, Curran MP. Lacosamide in partial-onset seizures. Drugs. 2009;69:449–59.

    Article  CAS  PubMed  Google Scholar 

  21. Canello W, Rosencranz B, Schmid B, Wierich W. Pharmacodynamic and pharmacokinetic evaluation of co-administration of lacosamide and an oral contraceptive (levonorgestrel plus ethinyloestradiol) in healthy female volunteers. Epilepsia. 2013;54:530–6.

    Article  Google Scholar 

  22. Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A. The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2013;54:66–74.

    Article  CAS  PubMed  Google Scholar 

  23. Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive lacosamide: 5 years clinical experience. Epilepsy Res. 2014;108:1385–91.

    Article  CAS  PubMed  Google Scholar 

  24. De Giorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18:322–4.

    Article  Google Scholar 

  25. Nizam A, Mylayarapu K, Thomas D, Briskin K, Wu B, Saluja D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia. 2011;52:e153–5.

  26. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, Palau J, Garcia M, Villaroya T, et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 2012;23:298–304.

  27. Flores L, Kemp S, Colbeck K, Moran N, Quirk J, Ramkolea P, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom. Seizure. 2012;21:512–7.

  28. Novy J, Bartolini E, Bell GS, Duncan JS, Sander JW. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epilepsy Res. 2013;106:250–6.

    Article  CAS  PubMed  Google Scholar 

  29. Villanueva V, Lopez FJ, Serratosa JM, Gonzalez-Giraldex B, Campos D, Molins A, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav. 2013;29:349–56.

  30. Paquette V, Culley C, Greanya ED, Ensom MHH. Lacosamide as adjunctive therapy in refractory epilepsy in adults: a systematic review. Seizure. 2015;25:1–17.

    Article  PubMed  Google Scholar 

  31. Zangaladze A, Skidmore C. Lacosamide use in refractory idiopathic primary generalised epilepsy. Epilepsy Behav. 2012;23:79–80.

    Article  PubMed  Google Scholar 

  32. Afra P, Adamolekun B. Lacosamide treatment of juvenile myoclonic epilepsy. Seizure. 2012;21:202–4.

  33. Hőfler J, Unterberger I, Dobesberger J, Kuchukhiaze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;53:e148–52.

    Article  Google Scholar 

  34. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenaw F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123:137–41.

    Article  CAS  PubMed  Google Scholar 

  35. Koubeissi MZ, Mayor CL, Estaphan B, Rashid S, Azar JN. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand. 2011;123:142–6.

    Article  CAS  PubMed  Google Scholar 

  36. Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive lacosamide in clinical practice-sodium blockade with a difference? Epilepsy Behav. 2011;22:499–504.

    Article  PubMed  Google Scholar 

  37. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007;75:192–6.

    Article  CAS  PubMed  Google Scholar 

  38. Gil-Nagel A, Elger C, Ben-Menachem E, Halasz P, Lopes-Lima J, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013;54:98–107.

  39. Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53:939–46.

    Google Scholar 

  40. Keating GM. Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures. CNS Drugs. 2014;28:583–600.

    Article  CAS  PubMed  Google Scholar 

  41. Hebeisen S, Pires N, Loureiro AI, Bonifacio MJ, Palma N, Whyment A, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122–35.

  42. Falĉao A, Vaz-da-Silva M, Gama H, Nunes T, Almeida L, Soares-da-Silva P. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinyloestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res. 2013;105:368–76.

    Article  PubMed  Google Scholar 

  43. Gupta DK, Bhoi SK, Kalita J, Misra UK. Hyponatraemia following eslicarbazepine therapy. Seizure. 2015;29:11–4.

    Article  PubMed  Google Scholar 

  44. Chung SS. Third generation antiepileptic drugs for partial-onset seizures: lacosamide, retigabine and eslicarbazepine acetate. Eur Neurol J. 2009;1:1–11.

    Google Scholar 

  45. Hufnagel A, Ben-Menachem E, Gabbai AA, Falcao A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res. 2013;103:262–9.

    Article  CAS  PubMed  Google Scholar 

  46. Villaneuva V, Serratosa JM, Guillamone E, Garces M, Giraldez BG, Toledo M, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of a 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108:1243–52.

  47. Massot A, Vivanco R, Principe A, Roquer J, Rocamora R. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results. Neurologia. 2014;29:94–10.

  48. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM, For the 205 Study Group. Randomized, multicenter dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68:1197–204.

  49. Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall, S, Shin P, On behalf of the RESTORE 2 Study Group, et al. Efficacy and safety of adjunctive retigabine/ezogabine in refractory partial epilepsy. Neurology. 2010;75:1817–24.

  50. French JA, Abou-Khalil BW, Leroy R, Yacubian EM, Shin P, Hall S, On behalf of the RESTORE 1 Study 301 investigators, et al. Randomized, double-blind, placebo-controlled trial of ezgogabine (retigabine) in partial epilepsy. Neurology. 2011;76:1555–63.

  51. Wuttke TV, Seebohn G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favours voltage-dependent opening of the Kv 7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005;67:1009–17.

    Article  CAS  PubMed  Google Scholar 

  52. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first in class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53:412–24.

    Article  CAS  PubMed  Google Scholar 

  53. Treven M, Koenig X, Assadpour E, Gantumur E, Meyer C, Hilber K, et al. The anticonvulsant retigabine is a subtype selective modulation of GABAA receptors. Epilepsia. 2015;56:647–57.

    Article  CAS  PubMed  Google Scholar 

  54. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11–27.

    Article  CAS  PubMed  Google Scholar 

  55. Ferron GM, Patat A, Parks V, Nolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady state in healthy subjects. Br J Clin Pharmacol. 2003;56:39–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2003;58:795–802.

  57. Brickell N, Gandhi P, van Landingham K, Hammond J, De Rossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia. 2012;53:606–12.

    Article  Google Scholar 

  58. Gil-Nagel A, Brodie MJ, Leroy R, Cyr T, Hall S, Castiglia M, et al. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies. Epilepsy Res. 2012;102:117–21.

    Article  CAS  PubMed  Google Scholar 

  59. Shkolnik TG, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discolouration-a new adverse effect of ezogabine. JAMA Dermatol. 2014;150:984–9.

    Article  CAS  Google Scholar 

  60. Evans SM, Akintayo O, Harrington CM, Kelly DB, Mcdonald SA, Lee W-J, et al. Pigmentation abnormalities (discolorations) associated with ezogabine/retigabine treatment: clinical effects. In: Presented at the 68th annual american epilepsy society meeting, 6–9 Dec 2014: Seattle (WA).

  61. Beacher NG, Brodie MJ, Goodall C. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate. BMC Oral Health. 2015;15(1):122.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Prescott JS, Evans GA. Pigmentary abnormalites (discoloration) associated with ezogabine/retigabine treatment: non clinical aspects. In: Presented at the 68th annual american epilepsy society meeting, 6–9 Dec 2014: Seattle (WA).

  63. Wehner T, Chinnasami S, Novy J, Bell GS, Duncan JS, Sander JW. Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure. 2014;23:876–81.

    Article  Google Scholar 

  64. Huber B, Bocchiccio M. A retrospective evaluation of retigabine in patients with highly therapy-resistant epilepsy. Epilepsy Behav. 2015;44:234–7.

    Article  PubMed  Google Scholar 

  65. Lerche H, Daniluk J, Lotay N, De Rossett S, Edwards S, Brandt C. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Seizure. 2015;30:93–100.

    Article  PubMed  Google Scholar 

  66. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–9.

    Article  CAS  PubMed  Google Scholar 

  67. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11:56–63.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Patsalos P. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel non competitive AMPA receptor antagonist. Epilepsia. 2015;56:12–27.

    Article  CAS  PubMed  Google Scholar 

  69. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54:1490–7.

    Article  CAS  PubMed  Google Scholar 

  70. Plosker GL. Perampanel as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012;26:1085–96.

    Article  CAS  PubMed  Google Scholar 

  71. Frampton JE. Perampanel: a review in drug-resistant epilepsy. Drugs. 2015;75(14):1657–68. doi:10.1007/s40265-015-0465-z.

    Article  CAS  PubMed  Google Scholar 

  72. Zaccara G, Giovanelli F, Cincotta M, Verrotti A, Grillo E. The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol. 2013;20:1204–11.

    Article  CAS  PubMed  Google Scholar 

  73. Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure phase III clinical trials. Epilepsy Res. 2015;114:122–30.

    Article  CAS  PubMed  Google Scholar 

  74. Ettinger AB, Lopresti A, Yang H, Williams B, Zhou S, Fain R, et al. Psychiatric and behavioural adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56:1252–63.

    Article  CAS  PubMed  Google Scholar 

  75. Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19:435–45.

    Article  PubMed  Google Scholar 

  76. Coyle H, Clough P, Cooper P, Mohanraj R. Clinical experience with perampanel: focus on psychiatric adverse effects. Epilepsy Behav. 2014;41:193–6.

    Article  PubMed  Google Scholar 

  77. Huber B. Increased risk of suicidality on perampanel (Fycompa)? Epilepsy Behav. 2014;31:71–2.

    Article  PubMed  Google Scholar 

  78. Steinhoff BJ, Hamer H, Trinka E, Schulze-Bonhage A, Bien C, Mayer T, et al. A multicentre survey of clinical experience with perampanel in real life in Germany and Austria. Epilepsy Res. 2014;1058:986–8.

    Article  Google Scholar 

  79. Gidal BE, Laurenza A, Hussein Z, Yang H, Fain R, Edelstein J, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1–9.

    Article  Google Scholar 

  80. Kramer LD, Satlin A, Krauss GL, French J, Perucca E, Ben-Menachem E, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014;55:423–43.

    Article  PubMed  Google Scholar 

  81. French JA, Krauss G, Wechsler R, Wang X, Diventura B, Brandt C, et al. Adjunctive perampanel for treatment of drug-resistant primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy: a double-blind randomized placebo-controlled phase III trial. Neurology. 2015;85:950–7.

  82. Piedad J, Rickards H, Besag FG, Cavana AE. Benefical and adverse psychiatric effects of antiepileptic drugs in patients with epilepsy. CNS Drugs. 2012;26:319–35.

    Article  CAS  PubMed  Google Scholar 

  83. Lin JL, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over a lifespan. Lancet. 2012;380:1180–92.

    Article  PubMed  Google Scholar 

  84. Geerts A, Brouwer O, Stroink H, Van Donselaar C, Peters B, Peeters G, et al. Onset of intractability and its course and time: the Dutch study of epilepsy in children. Epilepsia. 2012;53:741–51.

Download references

Author information

Authors and Affiliations

  1. Epilepsy Unit, Western Infirmary, Dumbarton Road, Glasgow, G11 6NT, Scotland, UK

    Martin J. Brodie

Authors
  1. Martin J. Brodie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin J. Brodie.

Ethics declarations

Funding

No funding was received in support of the publication of this article.

Conflicts of interest

Martin Brodie serves on the Scientific Advisory Boards of Eisai Ltd, UCB Pharma, GlaxoSmithKline, Lundbeck, Bial, GW Pharmaceuticals and Takeda. He is on the speakers’ bureau for Eisai Ltd, UCB Pharma, GlaxoSmithKline and Lundbeck, and has accepted travel grants for scientific meetings from Eisai Ltd, UCB Pharma and Lundbeck.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brodie, M.J. Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy. CNS Drugs 29, 893–904 (2015). https://doi.org/10.1007/s40263-015-0285-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-015-0285-4

Keywords

Search

Navigation